Eikon Therapeutics Overview
- Year Founded
-
2019
- Status
-
Public
- Employees
-
384
- Stock Symbol
-
EIKN
- Share Price
-
$4.77
- (As of Thursday Closing)
Eikon Therapeutics General Information
Description
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
Contact Information
Website
www.eikontx.comCorporate Office
- 230 Harriet Tubman Way
- Millbrae, CA 94030
- United States
Corporate Office
- 230 Harriet Tubman Way
- Millbrae, CA 94030
- United States
Eikon Therapeutics Timeline
Eikon Therapeutics Stock Performance
As of 19-Nov-2026, Eikon Therapeutics’s stock price is $4.77. Its current market cap is $258M with 54.2M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.77 | $5.17 | $4.72 - $17.40 | $258M | 54.2M | 558K | -$7.86 |
Eikon Therapeutics Financials Summary
As of 30-Sep-2026, Eikon Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 156,528 | |||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (334,291) | (314,801) | (234,954) | (247,947) |
| Net Income | (337,134) | (324,248) | (243,814) | (241,997) |
| Total Assets | 706,201 | 594,734 | 491,240 | 525,705 |
| Total Debt | 249,547 | 257,319 | 202,459 | 31,735 |
Eikon Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Eikon Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Eikon Therapeutics Comparisons
Industry
Financing
Details
Eikon Therapeutics Competitors (56)
One of Eikon Therapeutics’s 56 competitors is Relay Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Relay Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Pliant Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
| Fairjourney Biologics | Private Equity-Backed | Porto, Portugal | ||||
| Synlogic | Formerly VC-backed | Winchester, MA | ||||
| Valneva | Formerly VC-backed | Lyon, France |
Eikon Therapeutics Patents
Eikon Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026217628-A1 | Werner helicase inhibitors for treating dmmr and/or msi-h cancers | Pending | 08-Apr-2025 | ||
| WO-2026193291-A1 | Synthesis of substituted tricyclic compounds | Pending | 12-Mar-2025 | ||
| WO-2026107227-A1 | Compositions comprising usp1 inhibitors and methods of using the same | Pending | 13-Nov-2024 | ||
| WO-2026006796-A1 | Compositions comprising werner syndrome helicase inhibitors and methods of using the same | Pending | 27-Jun-2024 | ||
| WO-2025250888-A1 | Resiquimod in combination with a pd-1 or pd-l1 antagonist for treating cancer | Pending | 30-May-2024 | A61K31/4745 |
Eikon Therapeutics Signals
Eikon Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Eikon Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Eikon Therapeutics FAQs
-
When was Eikon Therapeutics founded?
Eikon Therapeutics was founded in 2019.
-
Where is Eikon Therapeutics headquartered?
Eikon Therapeutics is headquartered in Millbrae, CA.
-
What is the size of Eikon Therapeutics?
Eikon Therapeutics has 384 total employees.
-
What industry is Eikon Therapeutics in?
Eikon Therapeutics’s primary industry is Drug Discovery.
-
Is Eikon Therapeutics a private or public company?
Eikon Therapeutics is a Public company.
-
What is Eikon Therapeutics’s stock symbol?
The ticker symbol for Eikon Therapeutics is EIKN.
-
What is the current stock price of Eikon Therapeutics?
As of 19-Nov-2026 the stock price of Eikon Therapeutics is $4.77.
-
What is the current market cap of Eikon Therapeutics?
The current market capitalization of Eikon Therapeutics is $258M.
-
Who are Eikon Therapeutics’s competitors?
Relay Therapeutics, Pliant Therapeutics, Fairjourney Biologics, Synlogic, and Valneva are some of the 56 competitors of Eikon Therapeutics.
-
What is Eikon Therapeutics’s annual earnings per share (EPS)?
Eikon Therapeutics’s EPS for 12 months was -$7.86.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process